High levels of HER-2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in vivo

Clinical Cancer Research

Volumn 7, Issue 12, 2001, Pages 4230-4238

  Christensen, James G ^a   Schreck, Randall E ^a   Chan, Emily ^a   Wang, Xueyan ^a   Yang, Chris ^a   Liu, Luna ^a   Cui, Jean ^a   Sun, Li ^a   Wei, James ^a   Cherrington, Julie M ^a   Mendel, Dirk B ^a  

^a SUGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ARTICLE; AUTOPHOSPHORYLATION; CELL DEATH; CELL FUNCTION; ENZYME ACTIVE SITE; ENZYME PHOSPHORYLATION; GENE EXPRESSION REGULATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; INTRACELLULAR RECORDING; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TARGET CELL; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-2; HUMANS; MICE; MICE, NUDE; OVARIAN NEOPLASMS; PHOSPHORYLATION; PIPERAZINES; PYRIMIDINES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0035679211     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. The epidermal growth factor receptor and its inhibition in cancer therapy
2. Signal transduction by receptors with tyrosine kinase activity
3. Epidermal growth factor receptor inhibition in cancer therapy: Biology, rationale and preliminary clinical results
4. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors
5. The epidermal growth factor receptor and its ligands as therapeutic targets in human tumors
6. The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer
7. EGF-R expression in ductal breast cancer: Proliferation and prognostic implications
8. Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma
9. The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: Results of a 10 year follow-up study
10. Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma
11. Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: Correlation with clinical outcome and response to chemotherapy
12. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
13. Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members
14. Ligand discrimination by erbB receptors: Differential signaling through differential phosphorylation site usage
15. Take your partners, please - Signal diversification by the erbB family of receptor tyrosine kinases
16. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor
17. Specificity within the EGF family/ErbB receptor family signaling network
18. Epidermal growth factor receptors: Critical mediators of multiple receptor pathways
19. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358, 774: Dynamics of receptor inhibition in situ and antitumor effects in athymic mice
20. Anticancer efficacy of the irreversible EGFr tyrosine kinase inhibitor PD 0169414 against human tumor xenografts
21. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by co-administration of ZD1839 (Iressa), an inhibitor of EGF receptor tyrosine kinase
22. Intermittent oral ZD1839 (Iressa), a novel epidermal growth factor receptor tyrosine kinase inhibitor (Egfr-Tki), shows evidence of good tolerability and activity: Final results from a Phase I study
23. ZD1839 ("IRESSA") an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI): Pharmacokinetics in a Phase I study of patients with advanced cancer
24. Continuous administration of ZD1839 (Iressa), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in patients with five selected tumor types: Evidence of activity and good tolerability
25. A Phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), CP-358, 774, following platinum-based chemotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC)
26. A Phase II, multi-center study of the epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI), CP-358, 774, in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN)
27. HER-2/neu signal transduction in human breast ovarian cancer
28. ATP-competitive inhibitors of the EGF receptor tyrosine kinase: From research to clinic
29. Flk-1 as a target for tumor growth inhibition
30. The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function
31. Human epidermal growth factor receptor cDNA sequence aberrant expression of the amplified gene in A431 epidermoid carcinoma cells
32. An antigen immunologically related to the external domain of gp 185 is shed from nude mouse tumors overexpressing the c-erbB-2 (HER-2/neu) oncogene
33. Phase I studies of anti-epidermal growth factor receptor (EGFR) chimeric monoclonal antibody C225 in patients with EGFR overexpressing tumors
34. c-erbB-2 gene product directly associates with β-catenin and plakoglobin
35. c-erbB-2 gene product associates with catenins in human cancer cells
36. Colocalization of the p185HER2 oncoprotein and integrin α6β4 in Calu-3 lung carcinoma cells
37. α6β4 and α6β1 integrins associate with ErbB-2 in human carcinoma cell lines
38. 4 integrin and ErbB-2 receptor is required to promote phosphatidylinositol 3-kinase-dependent invasion
39. Integrin α2β1 recognizes laminin-2 and induces c-erb B2 tyrosine phosphorylation in metastatic human melanoma cells
40. A 50 kDa protein present in conditioned medium of COLO- 16 cells stimulates cell spreading and motility, and activates tyrosine phosphorylation of Neu/HER-2, in human SK-BR-3 mammary cancer cells